The Effect of DASH Diet on the Cardiometabolic Risks and Hepatic Function Among Type 2 Diabetic Patients
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01049321 |
Recruitment Status :
Completed
First Posted : January 14, 2010
Last Update Posted : January 14, 2010
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Type 2 Diabetic Patients | Dietary Supplement: DASH diet Dietary Supplement: a usual diabetic diet | Phase 4 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 36 participants |
Allocation: | Randomized |
Intervention Model: | Crossover Assignment |
Masking: | Triple (Care Provider, Investigator, Outcomes Assessor) |
Primary Purpose: | Treatment |
Study Start Date : | December 2008 |
Actual Primary Completion Date : | June 2009 |
Actual Study Completion Date : | December 2009 |
Arm | Intervention/treatment |
---|---|
Experimental: DASH diet
DASH: Dietary approaches to stop hypertension eating plan
|
Dietary Supplement: DASH diet
Other Name: Dietary aproaches to stop hypertension |
Placebo Comparator: Diabetic diet
Diabetic diet: a usual diabetic diet
|
Dietary Supplement: a usual diabetic diet |
- Cardio-metabolic risks [ Time Frame: 6 months ]
- Hepatic function [ Time Frame: 6 months ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 44 Years to 70 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Having type 2 diabetes
Exclusion Criteria:
- Having other chronic disease, hepatic or kidney disorders, cancer, hormone therapy

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01049321
Iran, Islamic Republic of | |
Shahid motahari hospital, Esfahan Esteel company, Iran | |
Isfahan, Iran, Islamic Republic of |
Principal Investigator: | Leila Azadbakht, PhD | Isfahan University of Medical Sciences |
Responsible Party: | Isfahan University of medical sciences, Isfahan University of Medical Sciences |
ClinicalTrials.gov Identifier: | NCT01049321 |
Other Study ID Numbers: |
DASH and cardiovascular risks |
First Posted: | January 14, 2010 Key Record Dates |
Last Update Posted: | January 14, 2010 |
Last Verified: | March 2008 |
Dietary Approach to Stop Hypertension weight coagulation DASH eating pattern. |